Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
|04/02/19||TGEM022||Innovative nanoparticle formulation
||Achieved higher content of drug, more homogeneous particle size distribution, lower cost (1/10) and easier mass production compared to conventional methods.
Easy to control particle size (2 nm ~ 500 nm).
Provide DDS function to the drug and stay the drug in the cell for a long time.
Enable re-development of compounds that abandon development with side effects and insufficient effect.
The substrate used in the nanoparticle formulation are used in approved medicines (FDA).
|02/12/19||TGEM021||A unique and effective transdermal delivery technology for small molecule drugs
||Can formulate patches with very high payload: Up to 50wt% achieved for drug and excipients, Extended release (24h up to 7-day) formulations possible, Fantastic adhesion, Water-resistant , Comfortable to wear and to remove. Efficient release of drug with improved skin penetration through formulation of free base/acid of API (not a salt)||Contact|
|01/11/19||TGEM020||Corporate alliance program with prestigious academia
||One of the best universities in the world is looking for corporate partners for its corporate alliance program. The program typically takes 3 years, and the corporate partner is expected to fund projects jointly undertaken by the university and the partner. The partner will have options to exercise further developments from the result of the projects. The university carefully selects its partners.||Contact|
|01/07/19||TGEM019||Novel patented topical delivery system
||The delivery particles are extremely effective at lodging into the stratum corneum, where they persist and gradually release their payload over a 24-48-hour time period. The payload can be most any small molecule or peptide. Eventually, the particles slough off as part of the skin-regeneration process. The particles can be easily tuned to control release rate. Depending on the chosen payload and the clinical objective, the particles can be as small as ~200 nanometers in size...and up to ~5 microns.
Demonstrated efficacy and safety in ~25 animal models of disease. Breakthrough technology with strong IP protection.
|12/20/18||TGEM018||Internalizing antibody discovery (Only for partnership)
||1) Screen hybridoma clones secreting cancer specific internalization antibodies with a patented high throughput assay 2) Panning living cancer cells with in-house constructed human naive ScFV library, wash away cell surface binders, apply cell lysate as sub-library; After several rounds of panning, enrich phages displaying antibodies with internalization ability
|12/20/18||TGEM017||Novel bispecific antibody discovery (Only for partership)
||IgG like bispecific antibody with new designed Fc mutations on top of "knob into hole" to enable super high heterodimer formation and purification as easy as a monoclonal antibody. Two versions have been developed: 1) Version 1: Two heavy chains plus one common light chain
-Common light chain can be designed from two parental light chains by modeling and structure analysis if they share more than 80% homology
-Biophysical and biochemical features of the two arms can be designed to meet functional needs (for example, imbalanced binding for CD20 and CD3 to balance safety and efficacy) and developability needs (to enable better isolation of heterodimer from homodimers)
2) Version 2: Two heavy chains plus two light chains
-VH1/VL1 interface and VH2/VL2 interface on the 3D model will be analyzed first to select those less likely allowing VL exchange and then optimized for reduced frequency of VL exchange
-The two arms will be differentiated for better heterodimer purification (similar to that in 1)
|12/20/18||TGEM016||Antibody Humanization And Optimization
||Detailed sequence analysis and 3D structure modeling
Identification of the best human germline sequence templates, grafting the rodent or rabbit antibody CDR regions into the human antibody frameworks
Identifying back-mutations and removing “hot spots” with developability issues
High throughput lead selection and evaluation
Efficient lead preparation for research purpose in house (>45 projects have been successfully completed!)
|12/20/18||TGEM015||Therapeutic Antibody Discovery
||Antigen design via bioinformatics and computer aided design
Antibody development via hybridoma and/or phage display technology
Screening mAb clones for high affinity, high expression, good efficacy and good developability
|12/10/18||TGEM014||Determination method for NK cell activity||Simple and quick method for determination of NK cell activity which is applicable to whole blood. The amount of IFN-γ or TNF-α produced by activated NK cells in whole blood is used as an indicator of NK cell activity.
Neither radioactive isotopes nor separation steps from blood cells are required.
|10/09/18||TGEM013||SUMO-fusion protein expression technology||Enables the efficient lower-cost production and purification of high quality, correctly folded proteins useful in all applications of protein preparation and drug discovery.
High expression levels
Variations optimized for insect, mammalian, E.coli and yeast.